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ABSTRACT: Systemic Lupus Erythematosus (SLE) is a 
chronic inflammatory disease of autoimmune origin that presents 
variable clinical manifestations, being progressive and potentially 
fatal, if not treated. Standard treatments include antimalarials, 
corticosteroids (CS) and immunosuppressants. However, despite 
a better understanding of the disease process, there is still a 
significant and unmet need for new treatment due to the continued 
high risk of mortality and progression of organ damage. Thus, the 
objective of the present study was making a bibliographical survey 
about the different treatments published for the management 
of SLE related to the patient’s clinical improvement. For that, 
the Lilacs, Scielo, PubMed and Google Scholar databases were 
used, and the Health Sciences Descriptors (DeCS) used were: 
“systemic lupus erythematosus”, “therapeutics” and “quality 
of life”. The selected articles were published in English and 
Portuguese, between the years 2014 and 2020. The references 
found showed that antimalarials and the infusion of fresh frozen 
plasma are the most effective therapeutic resources. In addition, 
vitamin D supplementation showed to have a beneficial function 
under the clinical picture of lupus patients. Another effective 
treatment for skin lesions was the use of pulsed dye laser. Thus, 
further studies are needed on demonstrating the effectiveness of 
different treatments for SLE in order to elucidate the efficacy and 
safety of the different therapies used.
Keywords:  Lupus  e ry thematosus ,  sys temic ; 
Immunosuppressive agents; Quality of life; Therapeutics.
RESUMO: O Lúpus Eritematoso Sistêmico (LES) é uma 
doença inflamatória crônica de origem autoimune que 
apresenta manifestações clínicas variáveis, sendo progressiva 
e potencialmente fatal, se não tratado. Os tratamentos padrões 
incluem antimaláricos, corticosteroides (CS) e imunossupressores. 
No entanto, apesar do melhor entendimento do processo da 
doença, ainda há uma necessidade significativa e não atendida de 
novo tratamento devido ao alto risco continuado de mortalidade 
e progressão de danos aos órgãos. Assim, o objetivo do presente 
estudo foi fazer um levantamento bibliográfico acerca dos 
diferentes tratamentos publicados para o manejo do LES 
relacionando com a melhora clínica do paciente. Para tanto, 
utilizou-se as bases de dados Lilacs, SciELO, PubMed e Google 
Acadêmico e os Descritores em Ciências da Saúde (DeCS) 
utilizados foram: “lúpus eritematoso sistêmico”, “terapêutica” e 
“qualidade de vida”. Os artigos selecionados foram publicados 
em língua inglesa e portuguesa, entre os anos de 2014 e 2020. As 
referências encontradas permitiram constatar que os antimaláricos 
e a infusão de plasma fresco congelado são os recursos terapêuticos 
com maior eficácia. Além disso, a suplementação com vitamina 
D apresentou mostrou ter função benéfica sob o quadro clínico 
de pacientes lúpicos. Outro tratamento efetivo para as lesões 
dermáticas foi a utilização de laser de corante pulsado. Desse 
modo, são necessários mais estudos acerca da demonstração da 
eficácia dos diferentes tratamentos para o LES, a fim de elucidar 
a eficácia e a segurança das diversas terapias utilizadas.
Palavras-chave: Lúpus eritematoso sistêmico; Imunossupressores; 
Qualidade de vida; Terapêutica.
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INTRODUCTION
The Systemic Lupus Erythematosus (SLE) corresponds to a chronic and inflammatory 
autoimmune disease characterized, mainly, by the loss 
of tolerance to nucleic acids and their binding proteins, 
which its pathophysiology can be explained by the 
generation of antinuclear antibodies (ANAs), formation 
and deposition of immunocomplexes in various organs and 
tissues. Its etiology is still unknown, and may be related 
to environmental, hormonal, immunological or genetic 
factors. Presents variable clinical manifestations, and it 
can be progressive and potentially fatal, if not treated1,2,3.
Worldwide, the incidence rates of SLE ranged from 
around 0,3 to 23,7 out of 100.000 people/year, meanwhile 
the prevalence of cases was from 6,5 to 178,0 out of 
100.000, and the variations observed in this rates reflect 
differences of age, gender, ethnical origin, socioeconomic 
condition and geographic region of the patients. Presents 
a higher prevalence in adults, women of childbearing age 
and non-Caucasians, as afro descendants, for example. In 
Brazil, it is estimated an SLE incidence of around 8,7 cases 
out of 100.000 people/year, and mortality is about 3 to 5 
times higher than that of the general population4,5.
As a multisystemic disease, it presents a 
heterogeneity of clinical manifestations with periods of 
accentuation and remission. The clinical picture includes 
the presence of monocutaneous manifestations, among 
which malar erythema and photosensitivity, in addition to 
oral ulcers, renal, cardiac, neurological, musculoskeletal 
and hematological impairment. Often, immunological 
manifestations such as the presence of antinuclear 
antibodies (ANA) in the blood are also observed5,6.
Regarding the diagnosis of SLE, the most accepted 
and well-disseminated criterion is that proposed by the 
American College of Rheumatology (ACR) in 1982, which 
establishes that the presence of SLE can be confirmed 
by pricing at least 4 of the following 11 classification 
criteria: malar erythema, discoid injury, photosensitivity, 
oral ulcer, arthritis, serositis (pleurite or pericarditis), renal 
alteration (proteinuria or cell cylinders), neurological 
disorders (convulsion or psychosis), hematological changes 
(hemolytic anemia with reticulocytosis, leukopenia, 
lymphopenia or thrombocytopenia), immunological 
changes (presence of native anti-DNA, anti-Sm or 
antiphospholipid antibodies) and antinuclear factors (ANF).
The development of therapies for SLE was limited 
by clinical and biological heterogeneity, including the 
diversity of gene expression signatures in peripheral 
blood patients. Standard treatments include antimalarials, 
corticosteroids (CS) and immunosuppressants. However, 
despite a better understanding of the disease process, there 
is still a significant and unmet need for new treatment due 
to continued high risk of mortality and progression of 
organ damage. In addition, chronic burden of symptoms 
and toxicity of immunosuppressive therapies also have a 
significant impact on the patient’s quality of life.
Several medications operate by modulating the 
immune system of the patients, since a fundamental 
aspect of SLE is the participation of B lymphocytes in the 
pathogenicity of the disease, once these cells are activated 
and from there migrate to different regions, where they 
undergo clonal expansion, proliferating, and forming the 
lymphoid aggregates that are deposited in the tissues. 
Among the most frequently used medications, there is 
Hydroxychloroquine, which acts by inhibiting the B-cell 
receptor and signaling; Cyclophosphamide, an annihilating 
agent of B and T cells and suppressor of antibody 
production; rituximab, anti-CD20 monoclonal antibody 
that leads to peripheral B-cell depletion; belimumab, 
responsible for reducing circulating B cells; calcineurin 
inhibitors such as cyclosporine and immunosuppressants 
such as Azathioprine, mycophenolate and tacrolimus. 
In view of the above, it is evident that SLE is a 
disease that negatively affects the quality of life of the 
affected individuals, bringing unfavorable symptoms 
to their survival, besides not presenting definitive cure. 
Thus, the aim of this study was to make a bibliographic 
survey about the different treatments published for the 
management of SLE related to the clinical improvement 
of the patient.
MATERIAL AND METHODS
This study refers to a bibliographic review with 
a qualitative approach, with a descriptive objective of 
national and international studies. The following steps 
were used to construct this review: identification of the 
theme; selection of the research question; data collection 
by searching the literature, in electronic databases, with 
establishment of inclusion criteria to select the sample; 
elaboration of an data collection instrument with the 
information to be extracted; evaluation of the studies 
included in the integrative review; interpretations of the 
results and presentation of the evidenced results.
For the preparation of the study, a search was 
carried out for productions in the databases Literatura 
Latino Americana e do Caribe em Ciências da Saúde 
(Lilacs), Scientific Electronic Library Online (SciELO), 
Public Medlines (PubMed) and Academic Google. For the 
choice of the appropriate descriptors for the body of work 
and corresponding to the study, a search was performed 
on the basis of Descritores em Ciências da Saúde (DeCS), 
resulting in the following descriptors: “systemic lupus 
erythesis”, “therapeutic” and “quality of life”. Besides 
this selection, to select the studies that best contributed to 
the research, Boolean operators were used, which were: 
“parentheses”, “AND” and “OR”.
With this, the articles that were fully available 
were filtered, in sequential order, indexed with a contained 
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time frame in the last 5 years and in the following idioms: 
English and Portuguese. The including criteria of inclusion 
were: articles that elucidate patients, regarding their ethnic 
or gender; studies that presented physiopathology and 
brought data referring to both treatments (SLE and their 
level of efficacy); and approached the quality of life of 
the patients in relation to the type of treatment adopted. 
Besides, the articles that were not available in full, were 
duplicated and opinion articles were excluded.
RESULTS AND DISCUSSION
The Chart 1 contains the main treatments found in 
modern literature to the treatment of SLE.
Chart 1: characterization of the main analyzed studies
Writers/Year Journal - Qualis Objective Main founds
Aranow et al.
2015
Arthritis Rheumatol.  
Qualis A1
Investigate the effects of vitamin D 
supplementation on the IFN sign in 
patients with SLE.
Vitamin D supplementation up to 4000 IU daily 
was safe and well tolerated but did not decrease 




Brit J Clin 
Pharmacol. 
Qualis A1
Evaluate the pharmacokinetics safety 
and biological activity of tabalumab, 
adminis tered intravenously or 
subcutaneously in individuals with 
rheumatoid arthritis or SLE.
A single dose of tabalumab administered was 
well tolerated. Tabalumab showed biological 
activity based on changes in peripheral numbers 




Clin Rheumatol.  
Qualis A4
E v a l u a t e  t h e  r e s p o n s e  t o 
immunosuppressive treatment of 
Hispanics with pure membranous 
lupus nephritis (MLN).
Mycophenolate mofetil MMF may be superior 
to intravenous Cyclophosphamide, while 






Evaluate the safety and efficacy of 
tabalumab on the SLE treatment.
Tabalumab resulted in a significant reduction in 
B cells and decreased levels of immunoglobulin 
G at both doses. There were no significative 
signs of kidney safety14.
Lima et al.
2017
Osteoporosis Int.  
Qualis A2
Evaluate the effect of vitamin D 
supplementation in patients with 
juveni le-onset  sys temic lupus 
erythesum (JoSLE).
Cholecalciferol supplementation for 24 weeks 
effectively improved bone microarchitecture 




SAGE J.  
Qualis B4
The aim of this report  was to 
share experience on the course of 
management of three cases diagnosed 
as SLE with C1q deficiency, in the light 
of the current literature.
This report suggests that severe skin lesions 
as observed in these patients with SLE with 
C1q deficiency, cannot be controlled with 
conventional immunosuppressive treatment. 
Instead, regular infusions of fresh plasma 




Rev Soc Bras Clín 
Med. Qualis C
Evaluate whether the overall well-
with SLE is affected by the use of 
antimalarials.
The use of antimalarials was associated with 
a lower occurrence of psychosis and kidney 
lesions, although it has led to a higher frequency 
of seizures. Regarding individual perception 
of quality of life, there was no significant 





Evaluate the efficacy and safety of 
Ustecinumab in the treatment of 
SLE in patients with moderate to 
severe activity despite conventional 
treatment.
The addition of Ustecinumab to standard 
treatment resulted in better efficacy in clinical 
and laboratory parameters than placebo in the 
treatment of active SLE. The results support 
the development of Ustecinumab as a new 





Evaluate the safety, tolerance and 
efficacy of Sirolimus in an open-up, 
prospective, biomarker-controlled 
clinical study.
The data show that a progressive 
improvement of the disease activity is 
associated with the correction of the 
specification of the pro-inflammatory T-cell 
lineage in patients with active systemic 
lupus erythematosus during 12 months of 
treatment with Sirolimus21.
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Writers/Year Journal - Qualis Objective Main founds
Kraaij et al.
2018
J Autoimmunity  
Qualis A1
Investigate whether the interference in 
the formation of immunocomplexes 
using a combination of rituximab 
(RTX) and belimumab (BLM), can 
decrease the formation of NETs and 
improve the disease.
The RTX þ BLM appeared to be safe and 
obtained clinically significant responses: 
low lupus disease status was achieved in 10 
patients, kidney responses in 11 patients and 
concomitant immunosuppressive medication 
was reduced in 14 out of the 16 patients3.
Mendez et al.
2018
Am Soc Nephrol. 
Qualis A1
Characterize the variability of B-cell 
depletion in peripheral blood after 
rituximab and evaluate its association 
with complete response in patients with 
lupus nephritis.
There was substantial variability in B-cell 
depletion in peripheral blood in patients with 






Evaluate the efficacy and safety 
of a 24-week course with low-
dose Leflunomide combined with 
prednisone in the induction treatment 
of proliferative lupus nephritis in 
Chinese patients.
Compared to Cyclophosphamide, low dose 
Leflunomide in combination with prednisone 
showed efficacy and safety in induction therapy 




Int League Assoc 
Rheumatol.  
Qualis B2
Seek higher remission rate of lupus 
nephritis using a combined strategy.
Treatment with a combined immunosuppressive 
agent is superior to routine Cyclophosphamide-
only therapy in lupus nephritis23.
Ishii et al.
2018
Japan Col Rheumatol. 
Qualis A2
Evaluate the efficacy and safety of 
bortezomib in the treatment of SLE in 
patients whose disease activity could 
not be controlled.
As bortezomib therapy for SLE is associated 
with many adverse reactions, the treatment 
indications with many adverse reactions should 
be carefully selected, and the protocols should 





Evaluate the efficacy, safety and 
tolerability of oral Baricitinib in 
patients with active SLE, that were 
receiving standard therapeutic 
treatment.
It was found that the daily use of 4 mg of 
Baricitinib showed improvement in SLE signs 
and symptoms, in addition to improving the 
clinical picture of patients with arthritis and 
joint pain. In other cases, it was observed that 
Baricitinib has positive effects under various 
dermatological conditions, such as atopic 





Evaluate the efficacy and safety of 
Atacicept, a B-lymphocyte stimulator 
antagonist, in patients with SLE.
The treatment with Atacicept showed effective 
evidence in the treatment of SLE, particularly in 
APH and serologically active patients. Severe 




Clin Exp Rheumatol.  
Qualis A3
Description of three patients with 
active SLE who achieved disease 
control after sequential treatment 
with rituximab and belimumab and 
discussion of the logic behind it.
A beneficial effect was observed after sequential 
treatment with rituximab and belimumab. All 
the patients achieved long-standing remission 




Adv. Rheumatol.  
Qualis C
Evaluate  the  effec t iveness  of 
psychoanalytic psychotherapy in a 
brief group to improve quality of 
life, depression, anxiety and coping 
strategies in patients with SLE.
Psychoanalytic psychotherapy was effective in 
improving many aspects of quality of life and a 
positive coping ability, in addition to reducing 





I n v e s t i g a t e  t h e  e f f i c a c y  o f 
Hydroxychloroquine in the treatment 
of skin manifestations according to 
LEC subtypes in Japanese patients.
Overall, HCQ was highly effective for the skin, 
as 87% of patients had at least some beneficial 
response in at least one type of skin lesion. 
In 74% of patients treated with concomitant 
systemic therapy, all disease activity decreased 
by about 32 weeks by additional administration 
of HCQ17.
Source: articles used to the realization of the study.
Chart 1: Characterization of the main analyzed studies                                                                                                       continuation
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Extracellular neutrophil traps (NETs) have been 
demonstrated as prominent autoantigens, leading to the 
production of autoantibodies relevant to the disease. 
In addition to NETs, which are proposed as important 
autoantigens for the development of ANAs, patients with 
SLE have hyperactivity characteristics of B lymphocytes, 
including the typical increase in circulating plasmocytes. 
Experimentally, it was observed that if these cells 
were removed from mouse “lupus models” by genetic 
manipulation or antibody therapy, the chain of immune 
reactions would be largely suppressed, including T-cells 
induced abnormalities2,3.
The combined use of rituximab and belimumab (RTX 
þ BLM) caused preferential reductions in autoantibody 
levels compared to physiological levels of antibodies, 
suggesting that autoantibody-secreting plasmocytes are 
more susceptible to this treatment. It has also been shown 
that RTX þ BLM has improved autoimmune phenomena 
by reducing circulated ANAs and regressing excessive 
formation of NETs mediated by immunocomplexes in 
SLE. Simultaneously, the RTX þ BLM caused significant 
clinical responses in patients with severe refractory SLE. 
The therapy with RTX þ BLM represents a promising new 
concept of treatment aimed specifically at autoimmunity 
in patients with SLE3. 
Another study compared the efficacy and safety of 
two doses of atacicept (75 and 150 mg) with placebo in 
patients with active SLE and with antibody level based on 
the fact that elevated serum levels of BLyS (B lymphocyte 
stimulator) and APRIL (a proliferation inducer) in patients 
with SLE correlate with disease activity and production of 
autoantibodies. These factors were promising goals for new 
research therapies and from this, the efficacy of atacicept, 
the double inhibitor APRIL and BLyS, was also suggested 
by this study, confirming its biological activity in the total 
reduction of B cells, plasmocytes and immunoglobulin in 
patients with SLE7.
Another recently investigated therapy for the 
treatment of SLE is Ustecinumab, which is a drug based on 
a monoclonal antibody, which binds to the p40 subunit by 
interleukin 12 and interleukin 23, the main inflammatory 
cytokines of the body. Its use has been shown to be effective 
in the treatment of SLE since it has as its main benefit the 
reduction of outbreaks of the disease after the 12th week 
of use. There has also been a considerable reduction in 
the number of autoantibodies and complement protein 
C3 in the bloodstream. It was considered effective for a 
both local and systemic treatment. The main disadvantage 
found was the increase in the number of urinary tract and 
nasopharynx infections, headache and respiratory diseases 
in the case group11.
In addition to investigations into alternative 
therapies to SLE, another medicine used in the treatment 
is antimalarials, which are associated with a lower 
occurrence of psychosis and lesions, although it led to 
a higher frequency of seizures in lupus patients. The 
individual perception of quality of life showed that the use 
of antimalarials (ATM) has no influence on the well-being 
of patients, except for mental health in tobacco users. The 
evidences allow us to consider ATM as safe drugs, which 
have more clinical benefits than adverse effects12.
Another point worth mentioning is that, despite 
the numerous advances in treatment for SLE, this disease 
remains with a high rate of morbidity and mortality. Recent 
studies show that Baricitinib, especially when used 4 mg/
day, is associated with significant clinical improvements 
in lupus patients. However, further studies on Baricitinib 
as a potential therapy for patients with SLE are needed13.
From the disease pathophysiology, it is important 
to highlight that in patients with SLE, B-cell activation 
factor (BAFF) levels are high. Thus, tabalumab, which is 
a monoclonal antibody that neutralizes the membrane, and 
soluble BAFF has been shown to be effective in reducing 
disease activity. This medicinal product had significant 
pharmacodynamic effects on the number of B cells ang IgG 
levels. However, after one year of treatment in patients with 
moderate to severe active SLE, but without severe active 
lupus nephritis, tabalumab had no effects compared to 
placebo in the ITT population (patients intending to treat)14.
Although many strategies targeting B-cell lines 
have been recently investigated, only belimumab has 
been approved for SLE therapy by Food and Drug 
Administration (FDA) from the USA. The bortezomib 
is a proteasome inhibitor that has been approved for the 
treatment of multiple myeloma (MM). However, the 
proteasome inhibitor also works effectively as an inhibitor 
to produce pro-inflammatory cytokines by regulating 
NF-kB activation. A recent study investigated the effects 
of bortezomib in patients with persistent SLE, despite 
the use of immunosuppressive therapies. In this small 
uncontrolled study, disease activity decreased significantly 
with treatment with bortezomib. These studies suggest that 
bortezomib can be effective in treating various symptoms 
of SLE by means of a mechanism other than inhibition of 
the production of anti-dsDNA antibodies. Therefore, for the 
indication of this treatment it is necessary to analyze each 
case individually and verify if the treated symptom really 
is of great importance for the treatment and improvement 
of the quality of life of the patient15.
It is known that hereditary deficiency of the early 
components of the complement system, especially C1q 
deficiency, is one of the reasons for early-onset SLE. 
Evidences suggest that the regular infusion of fresh frozen 
plasma (FFP) for the treatment of patients with SLE 
associated with C1q deficiency is of high efficacy, despite 
the risks of infection, hypocalcemia and acute lung injury 
associated with this type of transfusion are considerably 
low. It is observed that FFP administration normalizes 
the level of C1q for a very short period of time, however 
considerable and significant for the improvement of the 
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patient’s clinical picture16.
Another factor to be considered is that there is 
evidence to support the involvement of the interferon 
pathway type I in SLE. In this sense, the therapeutic benefit 
of the interferon pathway inhibition in patients with SLE 
has been reported in a study of the use of anifrolumab, 
a fully human IgG1κ monoclonal antibody for type 1 
interferon receptor subunit 1 inhibiting signaling by all 
type I interferons. Patients receiving anifrolumab were 
more likely to reduce glucocorticoid dose and severity of 
skin disease than patients receiving placebo. However, the 
differences between the groups in relation to swollen and 
sore joint counts and the updated rate of SLE seizures were 
not significant. Furthermore, this study was not designed 
to determine the durability of the effect or risks beyond 
52 weeks8.
A retrospective analysis of the efficacy of 
Hydroxychloroquine (HCQ) in skin treatment suggests that 
HCQ is shown to be extremely effective in the minimization 
of skin lesions. On the other hand, it was found that patients 
with SLE who had these skin lesions were more sensitive 
to treatment with HQC, as they had adverse effects to the 
detriment of improved signs and symptoms. There are 
several limitations in this research, since it was a small 
retrospective study and enrolled patients with different 
backgrounds, with different severities and durations of the 
disease. These factors can significantly affect the efficacy 
of HCQ, but further studies, with longer duration and with 
more significant samples, are needed to better verify the 
efficacy of this medicinal product in question17.
The randomized, double-blind study showed that 
vitamin D supplementation (cholecalciferol 50,000 IU/
week for six months) in patients with juvenile lupus 
improved bone microarchitecture, with the tibia as 
parameter. Another advantage of this study was that the 
treatment of patients with vitamin D supplementation 
remained stable during the six months of follow-up, thus 
allowing a more accurate analysis of the effect of this 
supplementation on this rheumatic condition18.
Another study suggests that vitamin D modulates 
immune response and blocks the induction of interferon 
(IFN) serum from patients with SLE. This research analyzed 
the potential impact of vitamin D3 supplementation in the 
overexpression of IFN-inducible genes in patients with 
SLE with vitamin D deficiency, and it was not observed 
reduction in IFN signature response after 12 weeks of 
vitamin D supplementation compared to placebo19.
A randomized research into the efficacy and safety 
of pulsed dye laser (PDL) in the treatment of lupus skin 
lesions suggests that lesions treated with PDL showed a 
significant higher decrease in erythema index and texture 
index compared to the control. Curiously, the polymerase 
chain reaction in real time showed a reduction in cytokines 
CXCL-9, 10, IFN- γ, IL-1β, TNF-α and TGF-β. In addition, 
the post-treatment lupus lesions showed a decrease in CD3, 
CD4, CD8 and CXCR3 positive cells20.
In a clinical and prospective study, rapamycin has 
been found to inhibit the proliferation of T lymphocytes 
and has been developed as a medicine under the generic 
designation of Sirolimus. In this research, the use of 
Sirolimus for SLE treatment has been satisfactory, as it 
showed a progressive improvement in disease activity. 
Which would be associated with the pro-inflammatory 
T-cell lineage in these patients. However, it is clear that 
further placebo-controlled clinical studies using Sirolimus 
are necessary, as a therapy in the various populations, in 
order to better elucidate the mechanism of action and 
efficacy of this drug in improving the quality of life of 
lupus patients21.
One of the new treatments with the best test result in 
the testing phase was Ustecinumab. The drug based on all-
human monoclonal antibodies directed to the p40 subunit 
shared by interleukin 12 and 23 has just passed from phase 
2 to phase 3, now being applied on a much larger scale. 
It was demonstrated sharp reduction in disease outbreaks, 
improvement in autoantibody and C3 protein levels and the 
possibility of both local and systemic treatment11.
 The treatment of membranous lupus nephritis 
(MLN) obtained promising results with the use of 
mycophenolate mofetil (MMF) and Azathioprine (AZA). 
The use of both drugs led to a complete remission rate of 
76.4% and 54.6% of each disease respectively and more 
than 89% responded to treatment of AZA and MMF alone. 
The study analyzed its combined use of corticosteroids in 
the Hispanic population and, with the results obtained, it 
is intended to continue the study with different ethnicities 
to ensure that the genetic factor of the population analyzed 
is not a determinant in the expected response to medicinal 
products12.
Cyclophosphamide was a medicine tested as an 
alternative to Leflunomide in the treatment of proliferative 
lupus nephritis. Its use in conjunction with glucocorticoids 
has had results close to standard treatments. Reduction 
of anti-dsDNA autoantibodies and proteinuria decreased 
significantly after ingestion of the combined medicinal 
product. However, the treatment is still limited, like the 
other ones, due to the fact that the small public analyzed 
(Chinese population) and the gene specificity that ethnicity 
can bring to treatment, with difficulty in generalizing its 
benefits and harms to other people22.
Another recent study, made in 2018, demonstrated 
the combined use of medicinal products through combined 
immunosuppressive treatment (CIST). The application 
of Cyclophosphamide, Hydroxychloroquine and some 
immunosuppressive agent has been shown to be superior 
to exclusive Cyclophosphamide therapy in the induction of 
remission in patients with lupus nephritis. The remission 
rate increased considerably form 20.8% of alone treatment 
to 39.5% and a lower treatment failure rate. However, 
the recurrence rate of the disease was constant in both 
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medications, with an average of 6 months of the return of 
the initial symptoms23.
In addition to conventional medical treatment, 
research reveals the importance of the psychological 
role in the treatment of SLE. Psychological assistance 
prepares patients for the symptoms that are manifested and 
the social weight that the disease will bring, serving as a 
complementation to the usual pharmacological treatment. 
The author also highlights a lower frequency of symptoms, 
lower level of anxiety and depression, and increased access 
to medical treatment. As much as the study has been shown 
to be beneficial, more research time is needed to understand 
how much the psychological factor can change the immune 
responses24.
CONCLUSION
In the present study, the main treatments used 
for SLE were presented. It was found that among the 
most effective are antimalarials medicine, such as 
Hydroxychloroquine, and infusion with fresh frozen 
plasma. In addition, vitamin D supplementation in these 
patients has a beneficial function under the clinical picture 
of lupus patients. An effective treatment for skin lesions 
also demonstrated in this study was with the use of pulsed 
dye laser.
However, many studies have not yet found, with 
complete safety, the benefits of these drugs in improving 
the quality of life of these patients, in addition, many of 
them showed relevant limitations especially regarding 
sample size and type of study. Therefore, further studies 
are needed on demonstrating the efficacy of the different 
treatments for SLE, with long-term follow-ups and the 
most satisfactory number of samples, to better elucidate the 
efficacy and safety of the various therapies used to improve 
the clinical picture of lupus patients. 
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